Indoco Remedies Limited has informed the Exchange regarding 'Business Responsibility & Sustainability Report for the financial year 2024-2025'.
INDOCO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Indoco Remedies has submitted its mandatory Business Responsibility and Sustainability Report (BRSR) for FY 2024-2025 to NSE and BSE, filed under SEBI's Listing Regulations. The company is a pure-play pharmaceutical manufacturer (100% of turnover) with 9 plants across India, no international plants, and exports contributing 38.70% of standalone revenue. Key figures include standalone turnover of ₹1,49,477.50 lakhs, net worth of ₹1,09,761.98 lakhs, 5,290 permanent employees, and 763 permanent workers, with women making up 25% of the board and female representation at 8.81% of total employees. The report highlights ESG initiatives such as replacing water/steam ejectors with dry vacuum pumps, introducing briquette boiler fuel, commissioning a new RO plant at Patalganga for water recycling, and digitalization through TrackWise, SAP, and LMS platforms. The BRSR was prepared on a standalone basis without external assurance.
This is a routine regulatory disclosure with no material change to business fundamentals. While the report offers transparency on ESG metrics, it carries no direct impact on stock price or shareholder value beyond standard compliance signaling.